Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
GSKKen Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.
ViiV Healthcare And The Pan-Canadian Pharmaceutical Alliance Finalize Negotiations For APRETUDE For HIV-1 Pre-Exposure Prophylaxis
GSKGSK Highlights New Approvals, Vaccine Momentum At JPMorgan Healthcare Conference
GSKGSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.
GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion
GSKGSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early treatment stages.
Illumina Launches Proteomics Pilot with 50,000 UK Biobank Samples, Partners with GSK, J&J, and Novartis
GSKGSK To Acquire Biopharma Firm IDRx for $1B And Earnout Of Up To $150M, Targets Precision Therapy for GIST Treatment
GSKThe FDA Has Accepted For Review GSK's Regulatory Application Of A Prefilled Syringe Presentation Of Shingrix For The Prevention Of Shingles (Herpes Zoster), An FDA Decision Is Expected By 20 June 2025
GSKPfizer's Progress on C. diff Vaccine and Pneumococcal Shot Wins Analyst Conviction
GSKGoldman Sachs analyst maintains Buy rating on Pfizer with $33 price target. Discusses update on 2nd-gen C. diff vaccine in Phase 2. Data expected in 2025.
GSK Announced Headline Results From FIRST-ENGOT-OV44 Phase 3 Trial Of Zejula (Niraparib) And Jemperli (Dostarlimab) In First Line Advanced Ovarian Cancer, The Trial Met Its Primary Endpoint Of Progression-free Survival, The Key Secondary Endpoint Of Overa
GSKMutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
GSKAccording to the Los Angeles Times, the total bird flue case count in the U.S. stands at 54; 31 cases are attributed to the dairy industry.
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
GSKGSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its primary endpoint.
GSK Announces Its GLISTEN Study Met Its Primary Endpoint, With Linerixibat Resulting In An Improvement In Itch
GSKGSK Raises Prospects For Withdrawn Blood Cancer Drug Blenrep To Return To US Market - Here's Why
GSKGSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.
GSK's AREXVY Vaccine Receives Expanded Approval In Canada For Adults Aged 50-59 At Increased Risk Of RSV, Offering Enhanced Protection Ahead Of Peak Season; Clinical Trials Ongoing For Adults 18-49
GSKGuggenheim Downgrades GSK to Neutral
GSKFirst Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
GSKSanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma control loss events and symptom improvements.
GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
GSKValisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. This follows Valisure's 2019 tests showing Zantac forms a carcinogen, prompting a whistleblower lawsuit seeking billions in damages.
GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
GSKGSK announced results from phase 3 trials SWIFT-1 and SWIFT-2, showing depemokimab's efficacy and safety in reducing severe asthma exacerbations.
GSK's Phase 3 Trials SWIFT-1 and SWIFT-2 Of Depemokimab Versus Placebo In Severe Asthma Patients With Type 2 Inflammation Met Primary Endpoints Of Reduction In Annualized Rate Of Clinically Significant Exacerbations (Asthma Attacks) Over 52 Weeks
GSKGSK Faces Whistleblower Suit From Lab That Exposed Zantac Risk; Wisner, Moore To Represent Valisure In Case; Valisure Claims GSK Hid Drug Risks While U.S. Paid For Zantac
GSKGSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
GSKGSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers.
GSK Announces Intention To Sell ~385M Shares In Haleon
GSKGSK's Panadol and Sensodyne-maker Haleon in Talks to Hire Banks
GSK